The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli ...

"Overall, metabolic responses to glucagon stimulation in individuals with type 1 diabetes are comparable to those in healthy ...

The following is a summary of “Metabolic Effects of Glucagon Stimulations in Type 1 Diabetes and Healthy Controls,” published ...

CHICAGO and ARLINGTON, Va. - The American Diabetes Association and a national supporter, Xeris Pharmaceuticals, have formed a multi-year strategic partnership to reinforce the importance of prescribin ...

With nearly half of Americans saying weight loss is a goal for them, it’s no wonder that interest in GLP-1 medications has ...

Xeris Pharmaceuticals has teamed up with the American Diabetes Association (ADA) to raise awareness of the importance of ...

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

Researchers from the Hebrew University of Jerusalem, Hadassah Medical Center, and the University of Pennsylvania found that the enzyme Glucose-6-phosphatase 2 (G6PC2) helps manage blood sugar levels ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Severely low blood sugar usually requires a glucagon injection. Speak with a healthcare provider to learn ways to prevent low blood sugar if you have frequent episodes of hypoglycemia.